Sleep Apnea: Wearables, Home Tests, and Who Should Test

TL;DR: Obstructive sleep apnea is common and badly under-recognized, and the wearable on your wrist has made it a live question for millions of people at once. The truth about these devices has a useful asymmetry: a watch or ring is good at raising a hand and poor at giving an all-clear. The Apple Watch and Samsung apnea features are cleared to flag signs of moderate-to-severe apnea and to nudge you toward testing, but they do not produce a diagnosis or a validated severity score, and because they miss a sizable share of true cases, a quiet device is not reassurance. If a wearable flags you, or if you snore heavily, stop breathing in your sleep, wake up tired, run hard-to-control blood pressure, or have atrial fibrillation, the next step is a medical sleep test. A home sleep test is a reasonable first move for an otherwise healthy person with a high chance of moderate-to-severe apnea, but it tends to undercount events, so a negative home test paired with strong symptoms calls for an in-lab study rather than relief. The one claim to resist, however common it is online, is that treating apnea will prevent a heart attack or stroke: treatment dependably improves sleepiness, snoring, quality of life, and blood pressure, and it is standard care for symptomatic apnea, but the major randomized trials did not show fewer cardiovascular events in people who were not sleepy. And a 2024 development changed the treatment map: tirzepatide, sold as Zepbound, became the first drug approved for moderate-to-severe apnea in people with obesity.

How common is sleep apnea, and how many people miss it?

Obstructive sleep apnea happens when the airway repeatedly narrows or closes during sleep, briefly cutting off airflow, dropping the blood oxygen, and pulling the brain up toward waking to reopen the throat, over and over through the night. It is far more common than most people assume. A large analysis estimated that close to a billion adults worldwide, around 936 million aged 30 to 69, have at least mild apnea, and roughly 425 million have the moderate-to-severe form.¹ In United States cohorts, moderate-to-severe sleep-disordered breathing affects on the order of 13 percent of middle-aged men and 6 percent of women.²

The striking part is how much of it goes unnamed. A classic study found that around 82 percent of men and 93 percent of women with moderate-to-severe apnea were undiagnosed, and modern estimates still put the undiagnosed share near 80 percent.³ The reasons are ordinary: snoring feels like a nuisance rather than a disease, the person asleep cannot observe their own breathing, and the daytime tax of poor sleep gets blamed on stress or age. Obesity is the strongest changeable driver, and risk climbs with age and is higher in men, but none of those are required, which is part of why so many cases slip past.

Can my Apple Watch or Oura ring detect sleep apnea?

This is the question the wearable era put on the table, and the answer has a shape worth learning. These devices are useful for raising suspicion and unreliable for ruling anything out.

The two features with regulatory clearance work differently and share a ceiling. The Apple Watch feature reads small wrist movements tied to breathing interruptions, accumulates them across roughly a month, and sends a notification when the pattern looks like moderate-to-severe apnea. In Apple's own validation, that notification was highly specific, near 98 percent, meaning a flag is meaningful and rarely a false alarm, but its sensitivity was only about 66 percent overall and closer to 43 percent for moderate cases.⁴ Read that carefully: a notification is a strong reason to test, but a silent watch misses a large fraction of true apnea, so the absence of a flag is not an all-clear. The Samsung Galaxy Watch feature, the first of its kind cleared in the United States, instead uses the watch's blood-oxygen sensor across two nights to detect signs of moderate-to-severe apnea, and it carries the same limit: it flags, it does not diagnose, and it will not reliably catch milder disease.

Rings and bands like Oura and Whoop sit further from a diagnosis still. They are wellness trackers rather than cleared apnea tests, and their blood-oxygen readings come from consumer sensors that are not medical oximeters. A jagged overnight oxygen trace or a restless-breathing pattern on one of these can be a reason to ask the question, but it is a prompt rather than an answer. The plain summary for any of them is the same: a flag from your wrist is a reason to get a medical test, and a reassuring reading in someone with symptoms means nothing on its own.

What is the AHI, and what do the numbers mean?

If you get tested, the headline number will be the apnea-hypopnea index, or AHI: the average number of breathing events per hour of sleep. An apnea is a near-total stop in airflow lasting at least ten seconds; a hypopnea is a partial drop paired with a fall in oxygen or a brief arousal. The conventional bands are simple: under 5 is normal, 5 to 15 is mild, 15 to 30 is moderate, and above 30 is severe. You may also see the oxygen desaturation index, which counts how often your blood oxygen falls, and which is the quantity consumer devices try to approximate.

It helps to hold the AHI loosely, because a single events-per-hour figure is a crude summary of a complex night. It says nothing about how deep or how long your oxygen fell, which is captured better by a measure called hypoxic burden that tracks cardiovascular risk more closely than the raw count.⁸ It also depends on the scoring rule used to define a hypopnea, so the same night can yield a different AHI under different definitions, and it ignores your symptoms. Two people with an identical AHI of 20 can have very different physiology and very different reasons to treat. The number is a starting point for a conversation rather than a verdict on its own.

Does treating sleep apnea protect your heart?

Here is the claim to handle with care, because the internet states it as settled and the trials do not. It is true that untreated apnea is linked with a long list of problems: hard-to-control high blood pressure, atrial fibrillation, stroke, heart disease, insulin resistance, daytime crashes, car accidents, and higher mortality in the most severe cases.⁵ Those associations are consistent and biologically sensible. The leap that does not hold is assuming that treating apnea therefore prevents those hard outcomes.

When researchers tested that directly, the results were sobering. Three major randomized trials gave CPAP, the mask-and-airflow treatment, to people with moderate-to-severe apnea and either established heart disease or a recent cardiac event, and none of them lowered the rate of heart attacks, strokes, or cardiovascular death compared with usual care.⁶¹¹¹² There are honest reasons the trials may have understated a benefit: people wore the mask only about three hours a night on average, below the level thought to help, and the studies mostly excluded the very sleepy, who are the people most expected to gain. So the fair reading is not that treatment is useless. It is that the cardiovascular payoff many assume is proven has not been proven, and the observational hints of benefit come mostly from people who stuck with the mask, a group that tends to be healthier for other reasons too.

What treatment does reliably do is worth stating plainly, because it is reason enough to treat symptomatic apnea: it improves daytime sleepiness, reduces snoring, lifts quality of life, and lowers blood pressure. The same pattern holds for atrial fibrillation, where untreated apnea tracks with more recurrences after an ablation and treating it is associated with better rhythm control, though here too the evidence is observational rather than from large randomized trials.¹³ Treat apnea to feel and function better and to help manage blood pressure and rhythm; do not promise yourself it will prevent a heart attack.

Home sleep test or the sleep lab: which do you need?

If testing is the right next step, there are two routes, and matching the route to the person matters. A home sleep apnea test is a small kit you wear in your own bed that records airflow, breathing effort, oxygen, and heart rate. A full in-lab study, called polysomnography, adds brain-wave, eye, and muscle sensors, so it can tell sleep from wake, stage your sleep, and catch things a home kit cannot, including central apnea and low breathing from other causes.

The sleep-medicine guideline is clear about the split.⁷ A home test is appropriate for an otherwise healthy adult with a high pretest chance of moderate-to-severe apnea and none of the complicating conditions. It is not the right tool when there is heart failure, significant lung or neuromuscular disease, chronic opioid use, suspected central apnea, or other major illness, all of which call for an in-lab study. And there is a limitation that anyone testing themselves should carry: because a home kit cannot tell when you are asleep, it spreads your events across the whole recording time and so tends to undercount them, with false-negative rates reported up to around 17 percent. The practical rule that follows is the important one: a normal home test in someone with strong symptoms does not rule apnea out, and should be followed by an in-lab study rather than taken as the end of the story.

Who should get tested?

Testing should follow symptoms and risk, and knowing the symptoms is the place to start. The classic ones are loud habitual snoring, breathing pauses someone else notices, gasping or choking awakenings, unrefreshing sleep, and daytime sleepiness heavy enough to interfere with driving or work. Morning headaches and waking to urinate repeatedly are common companions. Two medical findings raise the priority sharply: high blood pressure that resists several medications, and atrial fibrillation. A short questionnaire called STOP-BANG is a good triage tool that catches most true cases but over-flags, so it points toward testing rather than confirming anything.

The people most often missed are the ones who do not fit the stereotype. Women tend to present more subtly, with fatigue, insomnia, or mood symptoms rather than dramatic witnessed pauses, and are undercounted as a result. Lean people get apnea too, through the shape of the jaw, palate, and airway, so a normal weight does not clear you. And a fair number of people with confirmed apnea are simply not very sleepy. The lesson is that "I am not overweight and not tired" is not a rule-out. For the opposite reason, the US Preventive Services Task Force does not endorse screening every symptom-free adult, judging the evidence insufficient to weigh benefits against harms.⁹ That is a statement about testing people with no symptoms, and it says nothing against evaluating someone who has them.

What are the treatment options if you do have it?

Treatment has more choices than the mask most people picture. CPAP, which splints the airway open with gentle air pressure, is the most effective option and the usual first choice, and its main weakness is tolerance, since the benefit depends on wearing it. A custom oral appliance that holds the lower jaw forward is a good alternative for milder disease or for people who cannot tolerate CPAP. Positional strategies help when apnea happens mainly on the back, and an implanted nerve stimulator is an option for selected people who fail CPAP. Weight loss can change the disease itself when apnea is driven by excess weight.

The newest piece is a meaningful change. In 2024, a large trial showed that tirzepatide, a GLP-1-based weight-loss medication, cut the AHI substantially in adults who had moderate-to-severe apnea together with obesity, reducing events by roughly 25 to 29 per hour against a few per hour on placebo, alongside close to a fifth of body weight lost, and the FDA approved it, under the name Zepbound, for that group in December 2024.¹⁰ It is the first drug approved for sleep apnea, and it matters most for people whose apnea rides on obesity. The caveats keep it in proportion: it was studied only in people with obesity, it does not fix the jaw-and-airway anatomy that drives apnea in lean people, and many who improved did not reach a normal AHI. It is a major addition to the toolkit rather than a cure.

Guidance from the Clinic

"The wearable era has been good for sleep apnea in one way: it gets people asking. When a patient shows me an apnea flag from their watch, I take it seriously, because those flags rarely fire without reason. What I also tell them is the other half of the truth, that a quiet watch proves nothing, so if you snore, stop breathing at night, wake up unrefreshed, or your blood pressure will not come down, we test you regardless of what the device says. I pick the test to fit the person: a home kit for a healthy patient with obvious symptoms, a sleep lab when there is heart or lung disease or when a home test comes back normal but the story does not add up. And I am careful about the promise I make. Treating apnea will very likely help you feel better, sleep better, and get your blood pressure down, and that is worth doing. What I will not tell you is that it will prevent a heart attack, because the big trials did not show that. Honest expectations are part of good care here."

Related at Fishtown Medicine

• Your Apple Watch Says You Might Have AFib. Now What? - the companion "your watch flagged something" question, and the apnea-AFib link
• Tirzepatide (Zepbound, Mounjaro) - the drug now approved for obesity-related sleep apnea
• Sleep Apnea in Fit Men - apnea, testosterone, and why lean athletes are missed
• Sleep: The Foundation of Recovery - sleep architecture, HRV, and what wearables track well
• Sleep Disorders Treatment in Philadelphia - how we evaluate and treat sleep problems in the practice

Scientific References

1. Benjafield AV, Ayas NT, Eastwood PR, et al. "Estimation of the Global Prevalence and Burden of Obstructive Sleep Apnoea: A Literature-Based Analysis." Lancet Respiratory Medicine. 2019;7(8):687-698.
2. Peppard PE, Young T, Barnet JH, et al. "Increased Prevalence of Sleep-Disordered Breathing in Adults." American Journal of Epidemiology. 2013;177(9):1006-1014.
3. Young T, Evans L, Finn L, Palta M. "Estimation of the Clinically Diagnosed Proportion of Sleep Apnea Syndrome in Middle-Aged Men and Women." Sleep. 1997;20(9):705-706.
4. Apple Inc. "Estimating Sleep Apnea Risk from Breathing Disturbances: Sleep Apnea Notification Feature Performance." Validation white paper, 2024. (FDA 510(k) K240929.)
5. Yaggi HK, Concato J, Kernan WN, et al. "Obstructive Sleep Apnea as a Risk Factor for Stroke and Death." New England Journal of Medicine. 2005;353(19):2034-2041.
6. McEvoy RD, Antic NA, Heeley E, et al. "CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea (SAVE)." New England Journal of Medicine. 2016;375(10):919-931.
7. Kapur VK, Auckley DH, Chowdhuri S, et al. "Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2017;13(3):479-504.
8. Azarbarzin A, Sands SA, Stone KL, et al. "The Hypoxic Burden of Sleep Apnoea Predicts Cardiovascular Disease-Related Mortality." European Heart Journal. 2019;40(14):1149-1157.
9. US Preventive Services Task Force. "Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement." JAMA. 2022;328(19):1945-1950.
10. Malhotra A, Grunstein RR, Fietze I, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)." New England Journal of Medicine. 2024;391(13):1193-1205.
11. Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S, et al. "Effect of Obstructive Sleep Apnoea and Its Treatment with Continuous Positive Airway Pressure on the Prevalence of Cardiovascular Events in Patients with Acute Coronary Syndrome (ISAACC study)." Lancet Respiratory Medicine. 2020;8(4):359-367.
12. Peker Y, Glantz H, Eulenburg C, et al. "Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea (RICCADSA)." American Journal of Respiratory and Critical Care Medicine. 2016;194(5):613-620.
13. Shukla A, Aizer A, Holmes D, et al. "Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence: A Meta-Analysis." JACC: Clinical Electrophysiology. 2015;1(1-2):41-51.